CRC
NTLA icon

Curi RMB Capital’s Intellia Therapeutics NTLA Stock Holding History

Curi RMB Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,881
Closed -$348K – 529
2024
Q4 		$348K Sell
29,881
-9,306
-24% -$145K 0.01% 445
2024
Q3 		$805K Buy
39,187
+4,662
+14% +$107K 0.02% 367
2024
Q2 		$773K Hold
34,525
– – 0.02% 359
2024
Q1 		$950K Buy
34,525
+6,465
+23% +$180K 0.02% 352
2023
Q4 		$856K Hold
28,060
– – 0.03% 314
2023
Q3 		$887K Buy
28,060
+4,103
+17% +$159K 0.03% 289
2023
Q2 		$977K Hold
23,957
– – 0.03% 288
2023
Q1 		$893K Buy
23,957
+6,633
+38% +$260K 0.03% 291
2022
Q4 		$604K Sell
17,324
-7,775
-31% -$370K 0.02% 337
2022
Q3 		$1.41M Hold
25,099
– – 0.05% 255
2022
Q2 		$1.3M Hold
25,099
– – 0.04% 250
2022
Q1 		$1.82M Buy
25,099
+4,394
+21% +$372K 0.06% 203
2021
Q4 		$2.45M Buy
20,705
+3,477
+20% +$436K 0.07% 185
2021
Q3 		$2.31M Sell
17,228
-527
-3% -$79.8K 0.08% 192
2021
Q2 		$2.88M Hold
17,755
– – 0.1% 173
2021
Q1 		$1.43M Buy
+17,755
New +$1.19M 0.05% 219

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Curi RMB Capital's NTLA Position: Q1 2025 in Review

Curi RMB Capital sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 29,881 shares — an estimated $348K sold.

Curi RMB Capital first reported a position in NTLA in Q1 2021 and held it in 16 quarters. The position peaked at $2.88M in Q2 2021. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Curi RMB Capital reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Curi RMB Capital sold 29,881 Intellia Therapeutics shares in Q1 2025, an estimated $348K.
  • Curi RMB Capital first reported a position in Intellia Therapeutics in Q1 2021 and held it in 16 quarters.
  • Curi RMB Capital's Intellia Therapeutics position peaked at $2.88M in Q2 2021.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Curi RMB Capital's 13F filing for Q1 2025, filed 15 May 2025.